Anti-MOG antibody detection material, preparation method and application thereof, kit using detection material and detection method

Through the CBA detection method of glycosylation site mutation and low-temperature induced binding, the inconsistency of detection results and cytotoxicity in anti-MOG antibody detection is solved, the accuracy and sensitivity of the detection is improved, and the duration of antigen storage is extended, which is enhanced. Diagnostic ability of MOG antibody-related diseases.

CN118910073APending Publication Date: 2024-11-08WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411178118.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

现有的抗MOG抗体检测技术存在检测结果不一致、误差大、细胞毒性高、非特异性染色干扰及抗原保存不稳定等问题,导致检测准确性和灵敏度不足。

Method used

Through the combination of glycosylation site mutation, low temperature induction and protein protectant, CBA detection methods are constructed to improve the stability and affinity of MOG antigens expressed in cell membranes, reduce cytotoxicity, and enhance staining morphology clarity and antigen storage time.

Benefits of technology

It improves the accuracy and sensitivity of anti-MOG antibody detection, reduces non-specific staining interference, extends the duration of antigen storage, and enhances the diagnostic ability of MOG antibody-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to the technical field of antibody detection, in particular to an anti-MOG antibody detection material, a preparation method and application thereof, a kit using the detection material and a detection method. The preparation method specifically comprises the following steps: constructing a recombinant plasmid with a nucleotide sequence for coding MOG; transfecting the recombinant plasmid to an HEK 293T cell, culturing the HEK 293T cell at a low temperature, and adding an inducer for induction to obtain a cell slide expressing the MOG gene; the opportunity for adding the inducer is within 5-8 hours after the transfection; the anti-MOG antibody detection material is obtained by fixing a cell slide expressing an MOG gene by using a fixing solution and protecting the cell slide expressing the MOG gene by using a protein protective agent. The invention aims to construct a CBA methodology for anti-MOG antibody detection and research and development of a CBA detection method capable of effectively and rapidly detecting the anti-MOG antibody in serum, and the CBA detection method can be used for clinical auxiliary diagnosis and laboratory scientific research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of antibody detection, and in particular to an anti-MOG antibody detection material and a preparation method and application thereof, a kit using the detection material, and a detection method. Background Art

[0002] Myelin-oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin superfamily. It is specifically expressed on the surface of oligodendrocyte membranes and the outermost layer of myelin sheaths. Its expression level can reflect the degree of myelination. MOG has the function of regulating intercellular adhesion, skeletal proteins, and mediating the connection between myelin sheaths and immune cells. For decades, MOG has been considered a suspected antigen for demyelinating diseases of the central nervous system (CNS) and has been used to establish an animal model of multiple sclerosis (MS), namely experimental autoimmune encephalomyelitis (EAE) mice. Its immunogenicity and reactivity have been fully verified in animal models. Studies have found that antibodies with complete spatial conformation against MOG can mediate central demyelination, and have confirmed that anti-MOG antibodies can be detected in some patients with acute disseminated encephalomyelitis (ADEM), but are rare in MS. The three most common clinical manifestations of MOG antibody-associated disease (MOGAD) are ADEM, optic neuritis, and myelitis.

[0003] Anti-MOG antibodies are produced in peripheral blood, so the preferred test sample is serum, and cerebrospinal fluid testing only provides supplementary information. Positive anti-MOG antibodies in serum are the standard for diagnosing MOG antibody-related diseases. The early detection technology of anti-MOG antibodies was immature, and anti-MOG antibodies could only be detected by protein immunoblotting and ELISA. The test results were inconsistent and there were errors. With the improvement of detection technology, the cell substrate assay (CBA) test method was born. This method can screen natural proteins. In clinical practice, antibodies for autoimmune diseases are often detected using this method. This method has high sensitivity and high specificity. In 2001, the CBA test method was first used to detect anti-MOG antibodies in MS patients. The 2018 International Guidelines for MOG Antibody-Related Diseases proposed that the CBA test method is the best detection method for anti-MOG antibodies. Since then, the clinical application of the CBA test method for detecting anti-MOG antibodies has gradually increased, and research on MOG antibody-related diseases has also gradually increased. Studies have found that the anti-MOG antibody titer is related to the activity of the disease, specifically: the anti-MOG antibody titer in the acute phase is greater than the anti-MOG antibody titer in the remission phase; patients with long-term persistent anti-MOG antibody positivity are more likely to relapse; MOG antibody-related diseases with high anti-MOG antibody titers are more likely to relapse. By testing the anti-MOG antibody titer in the patient's serum and analyzing the changes in anti-MOG antibodies with disease relapse, clinicians can be guided to adopt different treatment strategies for different patients, ultimately reducing the risk of recurrence and disability and improving the prognosis.

[0004] Traditional protein immunoblotting and Elisa methods cannot obtain the complete spatial conformation of MOG and have low affinity. In the CBA method, since MOG expressed on the cell membrane is in a natural state, the MOG recognition epitope is completely exposed and can effectively bind to anti-MOG antibodies, which is closer to the reaction environment in the body. In recent years, with the popularity of CBA detection methods for MOG antibody-related diseases in clinical diagnosis, it is crucial to detect anti-MOG antibodies in patient serum (or cerebrospinal fluid) sensitively, efficiently and specifically, and to judge the severity of the disease by antibody titer.

[0005] In the early stage of preparing antigen slices, the CBA detection method requires the complete MOG gene CDS region sequence to be copied and inserted into the vector, and after a large number of cloning, the MOG plasmid containing the target gene is obtained; then it is transfected into cells (such as HEK293T cells) so that it can overexpress MOG antigen on the cell membrane, thereby obtaining antigen slices expressing MOG; and then it is fixed and stained to make a finished kit. When using the finished kit to detect patient serum (or cerebrospinal fluid), the cell staining morphology, the antibody titer read, and the stability of the results presented will have an important impact on the diagnostic results.

[0006] Furthermore, the CDS region sequence of the MOG gene obtained directly from the NCBI gene library will be toxic to the cells themselves after expression, causing a large number of cell deaths, thus affecting the judgment of the test results. At the same time, when this sequence is directly applied, the cell staining morphology is rounded when the results are presented, and there is a large amount of nonspecific staining in the negative control group, which interferes with the interpretation of the antibody titer, especially the weak positive samples. In addition, the expression efficiency of cells after transfection is also a key factor affecting the judgment of the results. In the ordinary transient mode, the MOG expression in the cells can be adjusted to the optimal level by controlling the cell state and the transfection system, but the upper limit is low, and it is very easy to miss the detection when detecting weak positive samples. In addition, the density of cells after transfection needs to be controlled in transient transfection to prevent the influence of excessive cell growth on the cell staining morphology. The stable preservation of the antigen is also very important for the finished antigen piece. Without intervention, the antigen protein is very easy to degrade under the influence of temperature, humidity, etc., which can easily cause instability in the test results.

[0007] Therefore, how to make the detection of anti-MOG antibodies more accurate and sensitive requires further study. Summary of the invention

[0008] The present application provides an anti-MOG antibody detection material and a preparation method and application thereof, a kit using the detection material and a detection method.

[0009] The present application aims to construct a CBA methodology for detecting anti-MOG antibodies, and develops a CBA detection method that can effectively and rapidly detect anti-MOG antibodies in serum, which can be used for clinical auxiliary diagnosis and laboratory scientific research.

[0010] The present application makes the cell staining morphology clearer and more complete in the CBA detection method, and the result interpretation is easier to distinguish; reduces the influence of non-specific staining; prolongs the antigen storage time, makes the detection results more stable, and thus improves the accuracy and sensitivity of anti-MOG antibody and MOG antibody-related disease detection.

[0011] In the present application, since the expressed MOG is concentrated on the cell membrane, the antigen binding site and spatial conformation can be completely preserved after fixation. Compared with the traditional protein immunoblotting and Elisa methods that require the destruction of the secondary structure of the protein or the antigen is coated to occupy part of the spatial binding site, the affinity of the antigen and antibody binding in the CBA detection method is higher and closer to the real reaction environment in the body, and the diagnosis of MOG antibody-related diseases is more convincing.

[0012] In a first aspect, the present application provides a nucleotide sequence encoding MOG.

[0013] A nucleotide sequence encoding MOG, comprising the nucleotide sequence shown in SEQ ID NO: 1.

[0014] In a second aspect, the present application provides a method for preparing an anti-MOG antibody detection material, using the following technical solution: A method for preparing an anti-MOG antibody detection material, the preparation method specifically comprising the following steps: (1) constructing a recombinant plasmid containing the above-mentioned nucleotide sequence encoding MOG; (2) transfecting the recombinant plasmid into cells, culturing the cells at low temperature, and adding an inducer to induce the cells to obtain a cell plate expressing the MOG gene; the cells are HEK 293T cells; The temperature used for the low temperature culture is 25-35°C, and the culture time is 48-72h; The inducer is added within 5-8 hours of culture after transfection; the ductility of the cell membrane is increased by adding the inducer; (3) first fixing the cell slide expressing the MOG gene with a fixing solution, and then protecting the cell slide expressing the MOG gene with a protein protecting agent, thereby obtaining an anti-MOG antibody detection material; The protein protectant is a mixed solution consisting of saccharides with a mass concentration of 2-15% and protease inhibitors with a molar concentration of 0.1-1.0 mmol / L.

[0015] In the present application, the target gene is a MOG gene CDS region sequence with a glycosylation site mutation. Glycosylation sites refer to specific amino acid residues on protein molecules that can be modified by glycosylation. By determining the glycosylation sites in proteins, the effects of glycosylation on protein structure and function can be understood, thereby regulating its biological activity and pharmacological properties. In the present application, the glycosylation sites of the MOG protein sequence are predicted by online prediction software, and then the sequence is mutated to change the MOG protein structure, reduce the toxic effects after cell expression, and improve the positive cell morphology after staining.

[0016] In the present application, the culture after transfection is coordinated with the induction of the inducer through low temperature conditions. On the one hand, the growth rate of cells is slow under low temperature conditions, which is convenient for controlling the cell density; on the other hand, the addition of the inducer will promote cell growth, and the low temperature culture conditions can make the cells grow without a large number of proliferation, and the cell membrane surface area is increased, which is conducive to the overexpression of MOG.

[0017] In terms of staining morphology, the cell membrane was in a normal growth state before induction, and the staining morphology was relatively round; after induction, due to the increase in cell membrane area, the cell morphology was more stretched and some of them had tentacle-like structures as shown in the staining results.

[0018] In terms of expression abundance, cells will express the target protein after transfection. The expression level of the target protein will increase with the extension of culture time within a certain period of time until the cell density reaches more than 90%. A large amount of target protein will be enriched in the cells, and from the presentation of staining results, there will be more positive cells.

[0019] To maintain vigorous growth of cultured cells, a constant and appropriate temperature is necessary. The standard temperature for HEK293T cell culture used in this application is 36.5±0.5°C. When the cells are placed at 25-35°C, the cells can still survive and grow, but the proliferation rate is slower than that of cells cultured at 37°C, which is conducive to prolonging the cell culture time and increasing the expression of MOG protein. Inducers can promote cell growth and increase the ductility of cell membranes. For example, EGF is epidermal growth factor, which can promote the growth of human epithelial cells. After transfection of a recombinant plasmid containing the MOG gene, the addition of epidermal growth factor EGF can effectively promote cell membrane growth and make the cell membrane morphology clearer after staining.

[0020] Culturing for 48-72 hours under low temperature conditions can effectively control the cell density after transfection. At this time, a large amount of MOG protein will be expressed on the cell membrane, and under the induction of EGF, the cell membrane is well extended. After fixation and staining, obvious positive cell membrane staining results will be observed under a fluorescence microscope.

[0021] The protein protectant is a combination of a sugar with a mass concentration of 2-15% and a protease inhibitor with a molar concentration of 0.1-1.0 mmol / L, so that the stability of the natural protein is enhanced. For example, the sugar can be sucrose and trehalose, and the protease inhibitor can be PMSF.

[0022] In this application, sucrose and trehalose are the best stabilizers for proteins in a dry state, which play a significant role in preventing changes in the secondary structure of proteins, and can also reduce the hydrolysis of target proteins by proteases; PMSF can inhibit various types of proteases and protect target proteins from protease degradation. In addition, after adding protein protectants, the anti-MOG antibody detection materials can be prevented from direct contact with air, reducing the risk of protein oxidation and microbial contamination, and extending the storage time of antigen proteins.

[0023] Since the fixed protein is easily degraded by the influence of temperature and humidity, in order to prevent the antigen in the test material from becoming ineffective, the present application treats the fixed cell slide with a protein protective agent. The carbohydrate substance in the protein protective agent can effectively adhere to the surface of the antigen, play a protective role, and extend the shelf life of the test material. The protein protective agent prepared in the present application can be removed after soaking in PBS buffer, and does not affect the experimental detection of subsequent test materials.

[0024] Optionally, the inducing agent is any one or more of EGF (epidermal growth factor), TGF-α (transforming growth factor α), HBEGF (heparin-binding EGF-like growth factor) and EPR (epiregulin).

[0025] Optionally, the amount of the inducer added is 0.5-0.8 ng / mL.

[0026] Optionally, the temperature during the preparation of the anti-MOG antibody detection material is no higher than 35°C.

[0027] In a third aspect, the present application provides an anti-MOG antibody detection material. The anti-MOG antibody detection material is prepared using the above preparation method.

[0028] Optionally, when the sample is tested using the test material, the temperature of the test process is no higher than 35°C.

[0029] Optionally, the detection process is carried out at room temperature.

[0030] In a fourth aspect, the present application provides a use of the above-mentioned anti-MOG antibody detection material in the preparation of a product for detecting anti-MOG antibodies.

[0031] In a fifth aspect, the present application provides a CBA detection kit, which includes the above-mentioned anti-MOG antibody detection material.

[0032] In a sixth aspect, the present application provides a CBA detection method using the above-mentioned anti-MOG antibody detection material, which adopts the following technical scheme: A CBA detection method using the above anti-MOG antibody detection material, the detection method specifically comprises the following steps: Add the sample to the reaction well of the anti-MOG antibody detection material for light-proof reaction; then wash with buffer solution, put into the dyeing tank for immersion, take out and discard the liquid in the reaction well after completion; continue to add fluorescent secondary antibody for light-proof reaction; then wash with buffer solution, add sealing medium, and observe the results.

[0033] In summary, the present application includes at least one of the following beneficial technical effects: The present application predicts the glycosylation sites of the MOG protein sequence and then mutates the sequence to change the MOG protein structure, reduce the toxic effects after cell expression, and improve the positive cell morphology after staining.

[0034] In the preparation method of the anti-MOG antibody detection material of the present application, the culture after transfection is coordinated with the induction of the inducer under low temperature conditions. On the one hand, the growth rate of cells under low temperature conditions is slow, which is convenient for controlling the cell density; on the other hand, the addition of the inducer will promote cell growth, and the low temperature culture conditions can make the cells grow without a large number of proliferation, and the cell membrane surface area is increased, which is conducive to the overexpression of MOG.

[0035] The present application treats the fixed cell slide with a protein protective agent. The carbohydrate substance in the protein protective agent can effectively adhere to the surface of the antigen, play a protective role, and extend the shelf life of the test material. The protein protective agent prepared in the present application can be removed after soaking in PBS buffer, and does not affect the subsequent experimental detection of the test material. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 These are pictures of the preparation process of the anti-MOG antibody detection material of the present application ((a) shows the anti-MOG antibody detection material after cutting; (b) shows a mosaic board with the anti-MOG antibody detection material after cutting pasted).

[0037] Figure 2 The test results of the test materials prepared in Examples 1-2 and Comparative Example 1 on positive serum samples and negative serum samples.

[0038] Figure 3 The test results of the test materials prepared in Example 1 and Comparative Example 2 on positive serum samples after being stored for 6 months. DETAILED DESCRIPTION

[0039] Before describing the embodiments of the present application in detail, it should be understood that the terms used herein are only used for the purpose of describing specific embodiments. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by ordinary technicians in the field to which the terms belong.

[0040] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of this application, unless otherwise specified, the meaning of "plurality" is two or more.

[0041] The endpoints and any values ​​of the ranges disclosed in this application are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0042] In the present application, the terms "comprise" or "include" are open expressions, that is, including the contents specified in the present application but not excluding other contents.

[0043] The present application provides a method for preparing an anti-MOG antibody detection material, an anti-MOG antibody detection material prepared by the preparation method, and an application of the anti-MOG antibody detection material in preparing a product for detecting anti-MOG antibodies.

[0044] The above preparation method specifically comprises the following steps: (1) constructing a recombinant plasmid containing the above-mentioned nucleotide sequence encoding MOG; (2) Transfecting the recombinant plasmid into cells, culturing them at low temperature, and adding an inducer to induce them, thereby obtaining a cell plate expressing the MOG gene; wherein the cells are HEK 293T cells; The temperature used for cultivation at low temperature is 25-35°C and the cultivation time is 48-72h; The timing of adding the inducer is within 5-8 hours of culture after transfection; the ductility of the cell membrane is increased by adding the inducer; (3) First, fix the cell slide expressing the MOG gene with a fixative, and then protect the cell slide expressing the MOG gene with a protein protective agent to obtain an anti-MOG antibody detection material; The protein protectant is a mixed solution consisting of saccharides with a mass concentration of 2-15% and protease inhibitors with a molar concentration of 0.1-1.0 mmol / L.

[0045] The present application also provides a CBA detection kit comprising the above anti-MOG antibody detection material, and a CBA detection method using the above anti-MOG antibody detection material.

[0046] The above CBA detection method specifically comprises the following steps: Add the sample to the reaction well of the anti-MOG antibody detection material and react in the dark; then wash with buffer and soak in a dye tank. After the reaction, take out and discard the liquid in the reaction well; continue to add fluorescent secondary antibody and continue to react in the dark; then wash with buffer, add sealing medium, and observe the results.

[0047] In order to make the purpose, technical scheme and advantages of the present application clearer, the technical scheme in the embodiments of the present application will be clearly and completely described below in conjunction with the accompanying drawings. Based on the embodiments of the present application, all other embodiments obtained by those skilled in the art without making creative work belong to the scope of protection of the present application. The embodiments described below are exemplary and are only used to explain the present application, and cannot be understood as limiting the present application.

[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0049] The present application is further described in detail below with reference to the embodiments.

[0050] Preparation Example This preparation example provides a nucleotide sequence encoding MOG. The nucleotide sequence includes the nucleotide sequence shown in SEQ ID NO: 1. The specific steps are as follows: (1) Select a human tissue or cell, extract genomic RNA, and prepare cDNA by reverse transcription.

[0051] (2) Design corresponding homologous recombination upstream and downstream primers for the MOG gene, and use the primers to perform PCR amplification on the MOG gene fragment to obtain the full-length CDS region (NCBI Reference Sequence: NM_206809.4).

[0052] (3) Analyze the corresponding gene mutation site through a protein glycosylation site prediction tool or database, and mutate the obtained genome using a point mutation kit to obtain the mutated MOG nucleotide sequence. The mutated MOG nucleotide sequence is the nucleotide sequence shown in SEQ ID NO: 1, that is, the CDS region sequence of the MOG gene with a glycosylation site mutation.

[0053] Example 1 This embodiment provides an anti-MOG antibody detection material.

[0054] The method for preparing the above anti-MOG antibody detection material specifically comprises the following steps: (I) Construction of recombinant plasmid containing the MOG gene CDS region sequence with glycosylation site mutation (1) Prepare a recombinant plasmid containing the mutated MOG nucleotide sequence. The specific steps are as follows: The target DNA fragment (MOG gene CDS region sequence with glycosylation site mutation) and the vector fragment provided in the preparation example were recovered and purified, connected by homologous recombination technology, and the target DNA fragment was inserted into a plasmid vector (pcDNA 3.1) to obtain a recombinant plasmid containing the mutated MOG nucleotide sequence.

[0055] (2) Introduce the recombinant plasmid containing the mutated MOG nucleotide sequence into DH5α competent cells, clone the plasmid and extract the plasmid. The specific steps are as follows: a. Introduce the above recombinant plasmid into DH5α competent cells.

[0056] b. Spread the DH5α competent cells introduced with the recombinant plasmid on an LB plate containing Amp.

[0057] c. Place the coated LB plate in a 37°C incubator for culture.

[0058] d. Large-scale extraction of plasmids from DH5α competent cells.

[0059] e. Perform restriction enzyme digestion on the plasmid and send it for sequencing.

[0060] The sequencing results showed that the recombinant plasmid containing the MOG gene CDS region sequence with glycosylation site mutation was successfully constructed.

[0061] (II) Obtaining cell slides expressing the MOG gene through low-temperature culture and EGF induction (1) Culture of HEK 293T cells a. Take out the HEK 293T cells from liquid nitrogen, quickly put them into a 37°C water bath, and gently shake the cryovial to thaw the cryopreservation solution.

[0062] b. Transfer the thawed cells to a centrifuge tube containing culture medium, collect the cells by centrifugation, centrifuge at 1500 rpm for 3 minutes at room temperature, and discard the supernatant.

[0063] c. Suspend the cells with complete culture medium, inoculate into the culture flask, shake well, and culture at 37°C and 10% CO2 saturated humidity until the cells are fully grown.

[0064] d. Discard the old culture medium, rinse the cells with PBS buffer, digest the cells with 0.25% trypsin, and add an equal volume of complete culture medium to terminate the digestion.

[0065] e. Transfer the digested cells to a 15 mL centrifuge tube and collect the cells by centrifugation at 1500 rpm for 3 min.

[0066] f. Add complete culture medium, blow the cells to make a single cell suspension, subculture at a ratio of 1:5, and expand the culture at 37°C and 10% CO2 saturated humidity.

[0067] (2) Cell plating and transfection a. After three subcultures, wait until the cells grow to a good state and have an appropriate density.

[0068] b. Discard the old culture medium, rinse the cells with PBS, digest the cells with 0.25% trypsin, add an equal volume of complete culture medium to terminate the digestion, transfer to a 15 mL centrifuge tube, centrifuge at 1500 rpm for 3 min to collect the cells, and discard the supernatant.

[0069] c. Add 1 mL of complete culture medium to resuspend the cells. Pipette 150-200 μL of cell suspension according to the cell density and add it to a 6-well plate pretreated with the adhesion reagent and containing 2 mL of complete culture medium, and mix evenly.

[0070] d. When the cell density reaches 70-90%, the recombinant plasmid containing the mutated MOG nucleotide sequence is transfected into HEK293T cells by cationic liposome transfection.

[0071] e. After transfection, the cells were cultured at 32°C and 10% CO2 under saturated humidity conditions.

[0072] f. Discard the culture medium every 6 hours, add 1 mL of serum-free culture medium to rinse, remove it, add 2 mL of complete culture medium, add EGF inducer at a final concentration of 0.6 ng / mL for induction, and then return to the 32°C incubator for continued culture.

[0073] g. Culture at 32°C for 50 hours to obtain cell slides that express a large amount of MOG gene on the cell membrane.

[0074] (III) Obtaining anti-MOG antibody detection materials that stably express the MOG gene by introducing protein protective agents The culture medium was removed, and 1 mL of PBS buffer was added to rinse the cell slides three times. The rinsed cell slides were placed in the prepared fixative (glutaraldehyde fixative with a mass concentration of 2.5%) for 10 min.

[0075] After fixation, remove the fixative, add 1 mL of PBS buffer to rinse 3 times, wash off the fixative, add a special protein protectant, protect for 5-10 minutes, remove the protein protectant, and obtain the CBA antigen piece, which is the anti-MOG antibody detection material. The effective ingredients of the protein protectant are trehalose with a mass concentration of 10%, sucrose with a mass concentration of 5%, and PMSF with a molar concentration of 0.1 mmol / L.

[0076] Add desiccant and place in a drying room for air drying. Cut the dried anti-MOG antibody detection material, paste it on a 4-well mosaic plate, and store it at 4-8℃ for a long time.

[0077] like Figure 1 As shown, Figure 1 Figure (a) shows the anti-MOG antibody detection material after cutting, and Figure (b) shows the mosaic board with the anti-MOG antibody detection material after cutting pasted.

[0078] Example 2 This embodiment provides an anti-MOG antibody detection material.

[0079] The difference between the preparation method of the above anti-MOGR antibody detection material and Example 1 is that in the preparation method of the detection material of this example, no EGF induction is added during low-temperature culture in step (ii).

[0080] Comparative Example Comparative Example 1 This comparative example provides an anti-MOG antibody detection material.

[0081] The difference between the preparation method of the above anti-MOGR antibody detection material and Example 1 is that in the preparation method of the detection material of this comparative example, the target gene used is the CDS region sequence of the MOG gene before mutation, which is the nucleotide sequence shown in SEQ ID NO: 2 (NCBI Reference Sequence: NM_206809.4).

[0082] Test 1 The samples were tested using the test materials of the embodiment and the comparative example. The samples can be 10-fold diluted serum samples or undiluted cerebrospinal fluid samples. The samples in this test are positive serum samples and negative serum samples.

[0083] The detection method using the above detection materials is as follows: (1) Soak the prepared anti-MOG antibody detection material in PBS buffer for 5 minutes. After the soaking, remove and discard the liquid in the reaction well.

[0084] (2) Add 10-fold diluted serum samples to the reaction wells of the anti-MOG antibody detection material in sequence, 50 μL per well, and place in a wet box for reaction for 30 minutes.

[0085] (3) After the reaction is completed, use PBS buffer to gently rinse the sample in the reaction well from one side and soak it in the dye tank for 5 minutes. After the reaction is completed, remove and discard the liquid in the reaction well.

[0086] (4) Add 50 μL of fluorescent secondary antibody (goat anti-human secondary antibody labeled with fluorescent Dylight 488) to the reaction well, and ensure that the fluorescent secondary antibody is in good contact with the reaction well. Place in a wet box for reaction for 30 minutes, and avoid light throughout the reaction process.

[0087] (5) Repeat step (3) and add mounting medium (a mixture of glycerol and PBS buffer in a ratio of 1:1 (v:v)) to the reaction wells, carefully covering with a coverslip to avoid bubbles.

[0088] (6) Observe the results under a fluorescence microscope.

[0089] The test results of Examples 1-2 and Comparative Example 1 are as follows: Figure 2 shown.

[0090] Depend on Figure 2 It can be seen that in Comparative Example 1, the MOG gene CDS region sequence before mutation was used, the cell staining morphology was rounded, the background signal was high, the interpretation of the antibody titer was interfered, and the expression rate was low; in Example 2, the MOG gene CDS region sequence after mutation was used. Although low-temperature culture was performed, EGF induction was not added, the cell staining morphology was improved, the apoptotic cells were reduced, the background signal was reduced, but the expression rate was still low; and in Example 1, the MOG gene CDS region sequence after mutation was used, and after low-temperature cell culture combined with EGF induction, the cell staining morphology was further improved, the cell membrane staining was clearer, the expression efficiency was greatly improved, the sensitivity was enhanced, and the interpretation of the antibody titer was more accurate, which is conducive to the analysis of anti-MOG antibody-related diseases through CBA detection method in clinical practice.

[0091] Comparative Example 2 This comparative example provides an anti-MOG antibody detection material.

[0092] The difference between the preparation method of the anti-MOGR antibody detection material and Example 1 is that: in the preparation method of the detection material of this comparative example, no protein protective agent is used for treatment.

[0093] Test 2 The positive serum samples were tested after being stored for 6 months using the test materials of Example 1 and Comparative Example 2. The test method was the same as that in the test 1.

[0094] Test results such as Figure 3 shown.

[0095] Depend on Figure 3 It can be seen that the addition of protein protective agent can effectively prolong the shelf life of the antigen in the anti-MOG antibody detection material, and the antigen titer remains almost unchanged.

[0096] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0097] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. A nucleotide sequence encoding MOG, characterized in that The nucleotide sequence includes the nucleotide sequence shown in SEQ ID NO:

1.

2. A method for preparing an anti-MOG antibody detection material, characterized in that: The preparation method specifically comprises the following steps: (1) constructing a recombinant plasmid carrying the nucleotide sequence encoding MOG according to claim 1; (2) transfecting the recombinant plasmid into cells, culturing the cells at low temperature, and adding an inducer to induce the cells to obtain a cell plate expressing the MOG gene; the cells are HEK 293T cells; The temperature used for the low temperature culture is 25-35°C, and the culture time is 48-72h; The inducer is added within 5-8 hours of culture after transfection; the ductility of the cell membrane is increased by adding the inducer; (3) first fixing the cell slide expressing the MOG gene with a fixing solution, and then protecting the cell slide expressing the MOG gene with a protein protecting agent, thereby obtaining an anti-MOG antibody detection material; The protein protectant is a mixed solution consisting of saccharides with a mass concentration of 2-15% and protease inhibitors with a molar concentration of 0.1-1.0 mmol / L.

3. The preparation method according to claim 2, characterized in that: The inducing agent is any one or more of EGF, TGF-α, HBEGF and EPR.

4. The preparation method according to claim 2, characterized in that: The amount of the inducer added is 0.5-0.8 ng / mL.

5. The preparation method according to claim 2, characterized in that: The temperature during the preparation of the anti-MOG antibody detection material is no higher than 35°C.

6. An anti-MOG antibody detection material, characterized in that: The anti-MOG antibody detection material is prepared by the preparation method according to any one of claims 1-5.

7. The anti-MOG antibody detection material according to claim 6, characterized in that: When the sample is tested using the test material, the temperature during the test is no higher than 35°C; Optionally, the detection process is carried out at room temperature.

8. Use of the anti-MOG antibody detection material according to claim 6 in preparing a product for detecting anti-MOG antibodies.

9. A CBA detection kit, characterized in that: The CBA detection kit comprises the anti-MOG antibody detection material according to claim 6.

10. A CBA detection method using the anti-MOG antibody detection material of claim 6, characterized in that: The detection method specifically comprises the following steps: adding a sample into the reaction well of the anti-MOG antibody detection material for light-proof reaction; then washing with a buffer solution, soaking in a dye vat, taking out and discarding the liquid in the reaction well after completion; continuing to add a fluorescent secondary antibody for light-proof reaction; then washing with a buffer solution, adding a sealing medium, and observing the results.